Historically, immunogenic pathways have been important targets in the management of metastatic ccRCC; cytokine therapy with interferon (IFN)-α and interleukin-2 (IL-2) were options for several years, however, their use was limited by significant toxicity and poor response rates [3]. The gene discussed is IL2; the disease is nonpapillary renal cell carcinoma.